Patents by Inventor Ahmad Hashash

Ahmad Hashash has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140051749
    Abstract: Crystalline solid forms and the amorphous form of the anti-HCV compound 5-(3,3-dimethylbutyn-1-yl)-3-[(cis-4-hydroxy-4-{[(3S)-tetrahydrofuran-3-yloxy]methyl}cyclohexyl){[(1R)-4-methylcyclohex-3-en-1-yl]carbonyl}amino]thiophene-2-carboxylic acid (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the crystalline forms.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 20, 2014
    Inventors: Ahmad Hashash, Scott Wolckenhauer, Bing Shi
  • Patent number: 8586601
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: September 3, 2010
    Date of Patent: November 19, 2013
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Patent number: 8501785
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: August 6, 2013
    Assignee: Novartis AG
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus O. Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Patent number: 8455662
    Abstract: Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.
    Type: Grant
    Filed: July 20, 2007
    Date of Patent: June 4, 2013
    Assignee: Novartis AG
    Inventors: Ahmad Hashash, Sean Ritchie, Kangwen Lin, Peng Shen, Augustus Okhamafe, Rampurna Gullapalli
  • Publication number: 20120308651
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Application
    Filed: June 4, 2012
    Publication date: December 6, 2012
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr H. Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Patent number: 8324389
    Abstract: The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: December 4, 2012
    Assignee: Novartis AG
    Inventors: Ahmad Hashash, Kangwen L. Lin, Augustus O. Okhamafe
  • Patent number: 8202998
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: June 19, 2012
    Assignee: Novartis AG
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr H. Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Patent number: 8138202
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: March 20, 2012
    Assignee: Sunesis Pharmaceuticals, Inc.
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20110086876
    Abstract: Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.
    Type: Application
    Filed: December 30, 2010
    Publication date: April 14, 2011
    Inventors: Anantha Sudhakar, Jeff Jacobs, Ahmad Hashash, Sean Ritchie, Hengqin Cheng
  • Publication number: 20100209418
    Abstract: The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.
    Type: Application
    Filed: February 28, 2008
    Publication date: August 19, 2010
    Inventors: Ahmad Hashash, Kangwen L. Lin, Augustus O. Okhamafe
  • Publication number: 20100168060
    Abstract: Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.
    Type: Application
    Filed: August 30, 2007
    Publication date: July 1, 2010
    Applicant: Novartis AG
    Inventors: Rampurna Gullapalli, Ahmad Hashash, Piotr H. Karpinski, Kangwen L. Lin, Eric M. Loeser, Augustus O. Okhamafe, Paul Allen Sutton, Eduardo Sy
  • Publication number: 20100040677
    Abstract: Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.
    Type: Application
    Filed: July 20, 2007
    Publication date: February 18, 2010
    Inventors: Ahmad Hashash, Sean Ritchie, Kangwen Lin, Peng Shen, Augustus Okhamafe, Rampurna Gullapalli
  • Publication number: 20060242746
    Abstract: An airbag equipped garment and deployment system for a motorcycle rider includes an inflatable garment shaped member for encompassing an upper body of a motorcycle rider and a mass of compressed gas. The system includes a first sensor for detecting the separation of the rider from the motorcycle and a second sensor for detecting the tilt of the cycle and deploying the gas when the rider separates from the motorcycle or the tilt exceeds a pre-selected value. A separate sensor senses a collision for deployment of gas in the event of a collision while a separate sensor deactivates the system until the speed of the motorcycle has reached a predetermined speed.
    Type: Application
    Filed: April 13, 2006
    Publication date: November 2, 2006
    Inventor: Ahmad Hashash